The Application of a New Maximum Color Contrast Sensitivity Test to the Early Prediction of Chiasma Damage in Cases of Pituitary Adenoma: The Pilot Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Our objective was to estimate the maximum color contrast sensitivity (MCCS) thresholds in individualswith chiasma opticum damage. Methods: The pilot study tested 41 people with pituitary adenoma (PA) and 100 age- and gender-matched controls. Patients were divided into two groups according to PA size, PA ≤1 cm or PA >1 cm. A new MCCS testprogram was used for color discrimination. Results: The mean total error score (TES) of MCCS was 1.8 in the PA ≤1 cm group (standard deviation [SD], 0.38),3.5 in the PA >1 cm group (SD, 0.96), and 1.4 in the control group (SD, 0.31; p < 0.001). There was a positivecorrelation between tumor size and MCCS result (r = 0.648, p < 0.01). In the group that had PA-producinghormones, the TES was 2.5 (SD, 1.09), compared to 4.2 value in the non-functioning PA group of patients thatdid not have clinically significant hormone excess (SD, 3.16; p < 0.01). In patients with normal visual acuity (VA)or visual field MCCS, the TES was 3.3 (SD, 1.8), while that in patients with VA <0.00 was 4.6 (SD, 2.9). Conclusions: Results of the MCCS test TES were 1.9 times better in patients with PA ≤1 cm compared topatients with PA >1 cm (p < 0.01). In PA patients with normal VA, the TES was 2.35 times worse than that ofhealthy persons (p < 0.01).
Abstract
Purpose: Our objective was to estimate the maximum color contrast sensitivity (MCCS) thresholds in individualswith chiasma opticum damage. Methods: The pilot study tested 41 people with pituitary adenoma (PA) and 100 age- and gender-matched controls. Patients were divided into two groups according to PA size, PA ≤1 cm or PA >1 cm. A new MCCS testprogram was used for color discrimination. Results: The mean total error score (TES) of MCCS was 1.8 in the PA ≤1 cm group (standard deviation [SD], 0.38),3.5 in the PA >1 cm group (SD, 0.96), and 1.4 in the control group (SD, 0.31; p < 0.001). There was a positivecorrelation between tumor size and MCCS result (r = 0.648, p < 0.01). In the group that had PA-producinghormones, the TES was 2.5 (SD, 1.09), compared to 4.2 value in the non-functioning PA group of patients thatdid not have clinically significant hormone excess (SD, 3.16; p < 0.01). In patients with normal visual acuity (VA)or visual field MCCS, the TES was 3.3 (SD, 1.8), while that in patients with VA <0.00 was 4.6 (SD, 2.9). Conclusions: Results of the MCCS test TES were 1.9 times better in patients with PA ≤1 cm compared topatients with PA >1 cm (p < 0.01). In PA patients with normal VA, the TES was 2.35 times worse than that ofhealthy persons (p < 0.01).
참고문헌 (27)
- Page RB, "Neurosurgery", pp.791~804 (1996), McGraw-Hill
- Nistor R, "Pituitary tumours", pp.264~272 (1996), NeuroReview
- Schoemaker MJ, "Risk factors for pituitary tumors: a case-control study", Cancer Epidemiol Biomarkers Prev, 18, pp.1492~1500 (2009)
- Schoemaker MJ, "Risk of pituitary tumors in cellular phone users: a case-control study", Epidemiology, 20, pp.348~354 (2009)
- Oruckaptan HH, "Pituitary adenomas: results of 684 surgically treated patients and review of the literature", Surg Neurol, 53, pp.211~219 (2000)
- Henkind P, "Duane’s clinical ophthalmology", pp.8~12 (1996), Lippincott-Raven Publishers
- Kanski JJ, "Clinical ophthalmology: a systemic approach", pp.480~483 (1994), Butterworth-Heinemann
- Poon A, "Patterns of visual loss associated with pituitary macroadenomas", Aust N Z J Ophthalmol, 23, pp.107~115 (1995)
- Ginsburg AP, "Contrast sensitivity and functional vision", Int Ophthalmol Clin, 43, pp.5~15 (2003)
- Liutkeviciene R, "Associations between color perception and optic nerve disk drusen", Medicina (Kaunas), 46, pp.821~826 (2010)
- Asa SL, "The pathogenesis of pituitary tumours", Nat Rev Cancer, 2, pp.836~849 (2002)
- Melmed S, "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.273~288 (2011)
- Ezzat S, "The prevalence of pituitary adenomas: a systematic review", Cancer, 101, pp.613~619 (2004)
- Asa SL, "Atlas of tumor pathology", pp.1~214 (1998), Armed Forces Institute of Pathology
- Cooper O, "Subclinical hyperfunctioning pituitary adenomas: the silent tumors", Best Pract Res Clin Endocrinol Metab, 26, pp.447~460 (2012)
- Sinkunas K, "Factors influencing an effect on the results of surgery for pituitary adenomas", pp.2008
- Birch J, "Diagnosis of defective colour vision", pp.149~156 (2001), Boston Butterworth-Heinemann
- Elgamal EA, "Pituitary adenomas:patterns of visual presentation and outcome after transsphenoidal surgery. An institutional experience", Internet J Ophthalmol Vis Sci, 4 (2007)
- Dhar MY, "Unusual visual manifestations of pituitary tumours", Kerala J Ophthalmol, 19, pp.147~155 (2007)
- Hollenhorst RW, "Diagnosis and treatment of pituitary tumours", pp.53~68 (1973), Excerpta Medica
- Anderson D, "Pituitary tumors and the ophthalmologist", Ophthalmology, 90, pp.1265~1270 (1983)
- Jayaraman M, "Multifocal visual evoked potential recordings in compressive optic neuropathy secondary to pituitary adenoma", Doc Ophthalmol, 121, pp.197~204 (2010)
- Dhasmana R, "Visual Fields at Presentation and after Trans-sphenoidal Resection of Pituitary Adenomas", J Ophthalmic Vis Res, 6, pp.187~191 (2011)
- Mejico LJ, "Clinical features associated with lesions other than pituitary adenoma in patients with an optic chiasmal syndrome", Am J Ophthalmol, 137, pp.908~913 (2004)
- Grochowicki M, "Contrast sensitivity function and pituitary adenoma: a study of 40 cases", Br J Ophthalmol, 74, pp.358~ (1990)
- Kasputyte R, "Changes of visual functions in patients with pituitary adenoma", Medicina (Kaunas), 49, pp.132~137 (2013)
- Gupta A, "Atrophy of myelinated nerve fibers in pituitary adenoma", J Clin Neuroophthalmol, 10, pp.100~102 (1990)